RCUS: Arcus Bio Net earnings per share (EPS TTM)

Arcus Biosciences (RCUS) - corporate logo

Scaling the immuno-oncology portfolio with the support of a pharma behemoth defines the potential of Arcus Biosciences, Inc. (RCUS), as confirmed by the 12-month net income per share trend shown on GURU.Markets, where the -3.65 level reflects the current value. Top scientists and R&D budgets ensure stability, while drug development follows scientific cycles, remaining independent of global GDP fluctuations.

RCUS Arcus Biosciences, Inc. Net earnings per share for the last 12 months (07/04/2022 - 11/16/2026)

Summary analytical data breakdowns for Arcus Corp (RCUS)

- share price and expert price forecast:
Fundamental valuation:RCUS - Arcus Corp
Flagship merchandise of Arcus Bio

Long-term partnerships of Arcus Biosciences, Inc. (RCUS) in immuno-oncology create inertial capital inflows, making the analysis of per-share earnings critical for evaluating the investment efficiency of future blockbusters. By examining the change in earnings per share over the last 12 months, an investor sees the net financial result distributed per share, allowing for an objective assessment of the business's fundamental value and the stability of market quotes.

Main competitors

IBRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year IMCR (Immunocore)|JANX: Net earnings per share (EPS TTM)|ZYME - Net earnings per share for the last four quarters|Earnings per share for the last twelve months tangotx.com|Net earnings per share for the last 12 months iovance.com (IOVA)|Earnings per share for the last twelve months Immatics NV (IMTX)|Net earnings per share for the last 12 months Xencor Corp XNCR|Compass Therapeutics Inc - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Replimune Inc. REPL|LYEL - Earnings per share for the last twelve months|IPHA (innate-pharma.com) - Earnings per share for the last 12 months|pyxisoncology.com (PYXS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Compugen Ltd. (CGEN)|Net earnings per share for the last 12 months IOBT|STRO - Net earnings per share for the trailing year|Net earnings per share for the last 12 months INKT (MiNK)|Earnings per share for the last four quarters HOWL|Net earnings per share (EPS TTM) IMMX (Immix Biopharma, Inc.)|Earnings per share for the trailing year ALXO|CUE - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months PDS Biotechnology Corporation|Sonnet BioTherapeutics Holdings Inc. (SONN) - Earnings per share for the last twelve months|MAIA Biotechnology - Earnings per share for the trailing year|LIMN (liminatuspharma.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) lavatherapeutics.com|Earnings per share for the last twelve months NextCure (NXTC)|LPTX: Earnings per one share for the last 12 months|Intensity Therapeutics, Inc. - Net earnings per share for the last 12 months|Sensei Biotherapeutics (SNSE) - Net earnings per one share for the last twelve months|TOVX: Net earnings per share for the last 12 months|Net earnings per share for the trailing year Gritstone bio (GRTS)|KA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NexImmune, Inc. (NEXI)|Earnings per share for the last twelve months turnstonebio.com|Net earnings per share for the last 12 months Vaccinex, Inc. (VCNX)|Earnings per share for the last twelve months Harpoon Therapeutics (HARP)